TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.

abstract：:Due to the lack of early diagnostic and effective treatment modalities, hepatocellular carcinoma (HCC) is still the most lethal cancer with a high mortality on a global scale. Recent studies have highlighted the key roles of microRNAs (miRs) in HCC development. In the study, we attempted to investigate the potential r...

journal_title：Cancer gene therapy

authors： Si T,Ning X,Zhao H,Zhang M,Huang P,Hu Z,Yang L,Lin L

更新日期：2020-11-30 00:00:00

abstract：:Recurrent fusion genes (FGs) with clinical significances in leukemias are mainly mutually exclusive, and the coexistence of different FGs has been rarely reported. In this study, we retrospectively analyzed the incidence, genetic characteristics, and prognosis of leukemias with concurrent pathogenic FGs, which commonl...

journal_title：Cancer gene therapy

authors： Chen X,Wang F,Wang T,Zhang Y,Ma X,Yuan L,Teng W,Guo L,Liu M,Liu M,Chen J,Nie D,Zhang Y,Zhou X,Wang M,Chen KN,Zhu P,Liu H

更新日期：2020-02-01 00:00:00

abstract：:The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte p...

journal_title：Cancer gene therapy

authors： Yen N,Ioannides CG,Xu K,Swisher SG,Lawrence DD,Kemp BL,El-Naggar AK,Cristiano RJ,Fang B,Glisson BS,Hong WK,Khuri FR,Kurie JM,Lee JJ,Lee JS,Merritt JA,Mukhopadhyay T,Nesbitt JC,Nguyen D,Perez-Soler R,Pisters KM,P

更新日期：2000-04-01 00:00:00

abstract：:Transforming growth factor-beta (TGF-beta) is a potent immunosuppressive cytokine produced by many tumor cells. Secretion of TGF-beta by malignant cells may therefore be a mechanism by which tumor cells escape destruction by tumor-specific T lymphocytes. In order to evaluate the role of tumor-derived TGF-beta on tumor...

journal_title：Cancer gene therapy

authors： Park JA,Wang E,Kurt RA,Schluter SF,Hersh EM,Akporiaye ET

更新日期：1997-01-01 00:00:00

abstract：:Tumor-endothelial interaction contributes to local prostate tumor growth and distant metastasis. In this communication, we designed a novel approach to target both cancer cells and their "crosstalk" with surrounding microvascular endothelium in an experimental hormone refractory human prostate cancer model. We evaluat...

journal_title：Cancer gene therapy

authors： Jin F,Xie Z,Kuo CJ,Chung LW,Hsieh CL

更新日期：2005-03-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC) recurrence is one of the leading causes of death after orthotopic liver transplantation (OLT). The sixth complement component (C6) is a late-acting complement protein that participates in the assembly of the membrane attack complex, which has an indispensable role in innate and acquired ...

journal_title：Cancer gene therapy

authors： Wang Z,Liao J,Wu S,Li C,Fan J,Peng Z

更新日期：2016-06-01 00:00:00

abstract：:Gene therapy designed to initiate apoptotic cell death provides a potentially effective method to treat cancer. A prerequisite for this approach is the identification of genes that function in distinct apoptotic pathways. Although apoptotic pathways initiated by receptors such as tumor necrosis factor receptor-1 are w...

journal_title：Cancer gene therapy

authors： Yin S,Hung MC,Goodrich DW

更新日期：2000-07-01 00:00:00

abstract：:Gene therapy for prostate cancer may be realized through transduction of whole genes, such as PSA or PSMA, into immunotherapeutic dendritic cells (DCs). An oncoretroviral vector encoding human PSMA and a bicistronic oncoretroviral vector encoding human PSA and cell surface CD25 cDNAs were constructed. Remarkably, tran...

journal_title：Cancer gene therapy

authors： Medin JA,Liang SB,Hou JW,Kelley LS,Peace DJ,Fowler DH

更新日期：2005-06-01 00:00:00

abstract：:Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h...

journal_title：Cancer gene therapy

authors： Pugalenthi A,Mojica K,Ady JW,Johnsen C,Love D,Chen NG,Aguilar RJ,Szalay AA,Fong Y

更新日期：2015-12-01 00:00:00

abstract：:The "bystander effect," produced by ganciclovir-mediated killing of cells transduced with a herpes simplex virus thymidine kinase (HSVtk) gene, defines the cooperative killing of non-HSVtk-transduced cells. In vitro, a major contributor to this phenomenon is metabolic cooperation involving transfer of cytotoxic small ...

journal_title：Cancer gene therapy

authors： Bi W,Kim YG,Feliciano ES,Pavelic L,Wilson KM,Pavelic ZP,Stambrook PJ

更新日期：1997-07-01 00:00:00

abstract：:The p16INK4 tumor suppressor gene encodes a protein that inhibits cyclin-dependent kinase 4, and its homologous deletion is common in human breast cancer. p16INK4 gene transfer has been reported to be efficacious in inducing growth inhibition of various human tumors such as brain, lung, prostate, and esophageal cancer...

journal_title：Cancer gene therapy

authors： Campbell I,Magliocco A,Moyana T,Zheng C,Xiang J

更新日期：2000-09-01 00:00:00

abstract：:Immune-isolation of nonautologous cells with microencapsulation protects these cells from graft rejection, thus allowing the same recombinant therapeutic cell line to be implanted in different recipients. This approach was successful in treating HER2/neu-expressing tumors in mice by delivering an interleukin-2 fusion ...

journal_title：Cancer gene therapy

authors： Cirone P,Shen F,Chang PL

更新日期：2005-04-01 00:00:00

abstract：:As an initial assessment of the feasibility of employing the adenovirus serotype 3 (Ad3) fiber knob as a locale for introducing a tropism-modifying motif, we generated an adenoviral vector containing a six-histidine tag genetically fused to the carboxy-terminus of the Ad3 fiber knob. The heterologous tag proved to be ...

journal_title：Cancer gene therapy

authors： Uil TG,Seki T,Dmitriev I,Kashentseva E,Douglas JT,Rots MG,Middeldorp JM,Curiel DT

更新日期：2003-02-01 00:00:00

abstract：:Let-7 miRNAs are involved in carcinogenesis and tumor progression through their roles in maintaining differentiation and normal development. However, there is little research focusing on the effects of let-7 on Wnt-activated self-renewal of breast cancer stem cells. By analyzing the expression levels of let-7 family m...

journal_title：Cancer gene therapy

authors： Sun X,Xu C,Tang SC,Wang J,Wang H,Wang P,Du N,Qin S,Li G,Xu S,Tao Z,Liu D,Ren H

更新日期：2016-04-01 00:00:00

abstract：:Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for oncolytic virotherapy. In squamous cell carcinoma (SCC) cells, the role of autophagy induced by neurovirulence gene-deficient HSV-1s in programmed cell death has not yet been elucidated. The oncolytic HSV-1 strain RH2, which lacks the γ3...

journal_title：Cancer gene therapy

authors： Furukawa Y,Takasu A,Yura Y

更新日期：2017-09-01 00:00:00

abstract：:Vesicular stomatitis virus (VSV) is being developed for cancer therapy. We created a recombinant replicating VSV (rrVSV) that preferentially infected Her2/neu expressing breast cancer cells. We now used this rrVSV to treat macroscopic peritoneal tumor implants of a mouse mammary tumor cell line stably transfected to e...

journal_title：Cancer gene therapy

authors： Gao Y,Whitaker-Dowling P,Griffin JA,Barmada MA,Bergman I

更新日期：2009-01-01 00:00:00

abstract：:We previously developed the "immunogene" approach toward cancer gene therapy using epidermal growth factor receptor (EGFR)-mediated endocytosis. Here, we describe an improved immunogene system, in which the antigen-binding (Fab) fragments of the monoclonal antibody (Ab) B4G7 against the human EGFR were conjugated with...

journal_title：Cancer gene therapy

authors： Chen J,Gamou S,Takayanagi A,Ohtake Y,Ohtsubo M,Shimizu N

更新日期：1998-11-01 00:00:00

abstract：:Arming oncolytic adenoviral vectors with anticancer transgenes that can be expressed in a tumor-selective manner may enable the engineering of vectors with increased potency, while retaining their safety profile. Armed oncolytic adenoviral vectors were constructed in which transgene expression has been linked via modi...

journal_title：Cancer gene therapy

authors： Robinson M,Ge Y,Ko D,Yendluri S,Laflamme G,Hawkins L,Jooss K

更新日期：2008-01-01 00:00:00

abstract：:To identify the differentially expressed genes (DEGs) and their transcription factors (TFs) in colorectal cancer (CRC). We performed an integrated analysis of microarray studies. Functional annotation and CRC-specific transcriptional regulatory network construction were performed. Expression of selected DEGs and TFs w...

journal_title：Cancer gene therapy

authors： Liu HY,Zhang CJ

更新日期：2017-06-01 00:00:00

abstract：:ING4 as a member of inhibitor of growth (ING) tumor suppressor family has potent inhibitory effects on a variety of tumors. Interleukin-24 (IL-24), a cytokine-tumor suppressor, also shows broad-spectrum and tumor-specific antitumor activities. In this report, we constructed an ING4/IL-24 bicistronic adenovirus (Ad-ING...

journal_title：Cancer gene therapy

authors： Zhu Y,Lv H,Xie Y,Sheng W,Xiang J,Yang J

更新日期：2011-09-01 00:00:00

abstract：:We examined the host immune response to the poorly immunogenic B16-BL6 melanoma, which was transduced to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) (450 ng/10(6)/24 h). Tumor growth after subcutaneous inoculation was not significantly altered, although an influx of neutrophils and monocytes/macr...

journal_title：Cancer gene therapy

authors： Arca MJ,Krauss JC,Aruga A,Cameron MJ,Shu S,Chang AE

更新日期：1996-01-01 00:00:00

abstract：:Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction and enhanced therapeutic benefit in a wide variety of cancer models. Here, we evaluated two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular recept...

journal_title：Cancer gene therapy

authors： Kubo S,Takagi-Kimura M,Kasahara N

更新日期：2019-02-01 00:00:00

abstract：:We have previously described oncolytic adenovirus (Ad) vectors KD3 and KD3-interferon (IFN) that were rendered cancer-specific by mutations in the E1A region of Ad; these mutations abolish binding of E1A proteins to p300/CBP and pRB. The antitumor activity of the vectors was enhanced by overexpression of the Adenoviru...

journal_title：Cancer gene therapy

authors： Shashkova EV,Kuppuswamy MN,Wold WS,Doronin K

更新日期：2008-02-01 00:00:00

abstract：:Interleukin-10 (IL-10) is a T helper type 2 (Th2) cytokine that suppresses Th1-mediated, cell-mediated immune responses and reciprocally enhances antibody-mediated responses. Previous studies, however, demonstrated that forced expression of the IL-10 gene in tumor cells could unexpectedly produce antitumor effects. We...

journal_title：Cancer gene therapy

authors： Kawamura K,Bahar R,Natsume W,Sakiyama S,Tagawa M

更新日期：2002-01-01 00:00:00

abstract：:Although the high transfection efficiency with adenovirus in vitro is well documented, it is still not clear whether adenoviral vectors are effective in vivo in solid tumor models. In our preliminary experiment, transduction of tumor tissue was limited to just around the injection site after intratumoral injection of ...

journal_title：Cancer gene therapy

authors： Lee SG,Yoon SJ,Kim CD,Kim K,Lim DS,Yeom YI,Sung MW,Heo DS,Kim NK

更新日期：2000-10-01 00:00:00

abstract：:Although gene therapies using tissue-specific promoters have been reported to be a promising tool for treating cancers, few studies have explored this possibility for uterine cervical cancer. MN/CA9 is a transmembrane glycoprotein that was first identified in the human cervical carcinoma cell line, HeLa. Since MN/CA9 ...

journal_title：Cancer gene therapy

authors： Lim HY,Ahn M,Chung HC,Gardner TA,Kao C,Lee SJ,Kim SJ

更新日期：2004-08-01 00:00:00

abstract：:Combination therapy with replicative oncolytic viruses is a recent topic in innovative cancer therapy, but few studies have examined the efficacy of oncolytic adenovirus plus replication-deficient adenovirus carrying a suicide gene. We aim to evaluate whether an E1A, E1B double-restricted oncolytic adenovirus, AxdAdB-...

journal_title：Cancer gene therapy

authors： Fukuda K,Abei M,Ugai H,Kawashima R,Seo E,Wakayama M,Murata T,Endo S,Hamada H,Hyodo I,Yokoyama KK

更新日期：2009-02-01 00:00:00

abstract：:Cancer gene therapy approaches are often designed as single-agent treatments; however, greater therapeutic effect might be obtained if combined with an established conventional treatment regimen such as chemotherapy. In this context, conditional promoters are useful tools, because they may be induced by therapeutic mo...

journal_title：Cancer gene therapy

authors： Walther W,Stein U,Fichtner I,Alexander M,Shoemaker RH,Schlag PM

更新日期：2000-06-01 00:00:00

abstract：:Endothelial cells and endothelial cell precursors encoding a therapeutic gene have induced antitumor responses in preclinical models. Culture of peripheral blood provides a rich supply of autologous, highly proliferative endothelial cells, also referred to as blood outgrowth endothelial cells (BOECs). The aim of this ...

journal_title：Cancer gene therapy

authors： Bodempudi V,Ohlfest JR,Terai K,Zamora EA,Vogel RI,Gupta K,Hebbel RP,Dudek AZ

更新日期：2010-12-01 00:00:00

abstract：:Previous studies have indicated that the cytokine interleukin (IL)-21 may induce both innate and adaptive immune responses against tumors. The goal of this study was to evaluate a new adoptive immunotherapy strategy that combined lymphocytes from mice immunized with a murine myeloma vaccine secreting murine IL-21 (mIL...

journal_title：Cancer gene therapy

authors： Dou J,Wu Y,Wang J,Zhao F,Chu L,Liu C,Wen P,Hu W,Hu K,He XF,Gu N

更新日期：2010-10-01 00:00:00